Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines
(Thomson Reuters ONE) -
LOWELL, Mass., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, a
leading provider of automated, non-destructive, rapid microbial detection, is
pleased to announce the receipt of a $7.3 million contract from the Biomedical
Advanced Research and Development Authority (BARDA) for the implementation of a
rapid sterility test for vaccines. This awarded grant is part of BARDA's Advance
Development of Medical Countermeasures for Pandemic Influenza, which focuses on
improving the government's responsiveness to future pandemic threats. When
combined with Rapid Micro Biosystems' automated Growth Direct(TM) detection
system, the rapid sterility test will result in faster release of vaccines and
other sterile products. Timely delivery of these products carries multiple
public benefits, principally in facilitating rapid responses to pandemic or
emerging infections, agents of bioterrorism, and availability of life saving
medicines.
"Our continuing relationship with BARDA demonstrates the critical need for rapid
sterility testing as part of our response to immediate health threats," said
Robert Spignesi, Chief Executive Officer at Rapid Micro Biosystems.
"Our unique detection technology will show contamination within hours and will
provide results in half the time of the traditional 14-day test," said Edward
Ognibene, Vice President Development at Rapid Micro Biosystems.
The team at Rapid Micro Biosystems has extensive experience in product
development, manufacturing, and service of rapid microbial quality control
products, and has previously worked successfully with BARDA to develop the
fundamental technology for a rapid sterility test. Upon completion of the
program, the resulting product will make valuable improvements to the quality
control release of sterile vaccines and other lifesaving pharmaceutical products
and will immediately benefit the public.
About Rapid Micro Biosystems
Rapid Micro Biosystems creates innovative products for fast, accurate, and
efficient detection of microbial contamination in the manufacture of
pharmaceuticals, biologics, medical devices, and personal care products. The
company's Growth Direct(TM) System is the first and only non-destructive,
growth-based system to automate microbial quality control testing. By automating
and accelerating the detection and enumeration of environmental monitoring,
bioburden and sterility testing, the Growth Direct decreases QC testing time,
ensures data integrity, and reduces the risk of costly contamination events. For
more information about Rapid Micro Biosystems visit www.rapidmicrobio.com
Contact:
Eugenia Kendrick
Rapid Micro Biosystems
ekendrick(at)rapidmicrobio.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Rapid Micro Biosystems via GlobeNewswire
Datum: 23.10.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 564760
Anzahl Zeichen: 3430
contact information:
Town:
Lowell, MA
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 215 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Rapid Micro Biosystems Awarded a Contract by Biomedical Advanced Research and Development Authority (BARDA) for the Implementation of a Rapid Sterility Test for Vaccines"
steht unter der journalistisch-redaktionellen Verantwortung von
Rapid Micro Biosystems (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
